The company’s system is placed in the subclavian vein, a blood vessel that runs under the collar bone bringing deoxygenated ...
The study met its primary endpoint with no procedure or device related serious adverse events reportedRUTHERFORD, N.J., Feb. 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: GCTK) (“Glucotrack” or the “Company” ...